Faculty Advisor

Manning, Amity L.

Abstract

Acute Myeloid Leukemia (AML) is the most common type of blood cancer to occur in adults. AML patients are commonly treated with chemotherapeutic approaches. However, these approaches target pathways common in all proliferating cells, resulting in damaged healthy tissues. Currently, the identification and development of therapies that specifically or preferentially impact growth of leukemia cells is in high demand. Alisertib, an inhibitor of Aurora A kinase, is being investigated clinically as a co-therapeutic for AML. Our studies have focused on exploring the molecular effects of Aurora A inhibition, and investigating cellular biomarkers that may predict drug sensitivity in AML patients. Our results suggest that an increased centriole number confers resistance of AML cells to Alisertib.

Publisher

Worcester Polytechnic Institute

Date Accepted

March 2017

Major

Biology and Biotechnology

Project Type

Major Qualifying Project

Accessibility

Unrestricted

Advisor Department

Biology and Biotechnology

Share

COinS